Skip to main content

Table 4 Partial utilities of therapeutic attributes among caregivers and neurologists

From: Therapeutic preference for Alzheimer’s disease treatments: a discrete choice experiment with caregivers and neurologists

Therapeutic attribute

Caregivers (N = 137)

Neurologists (N = 161)

aMean (SE)

SD (SE)

aMean (SE)

SD (SE)

Clinical effects (average): 1-year increment

0.47 (0.08)

0.65 (0.01)

0.82 (0.08)

0.70 (0.01)

Clinical effects (variation): wide vs. narrow

0.12 (0.08)

0.70 (0.01)

0.14 (0.07)

0.75 (0.01)

Biomarker response (amyloid clearance): 10% increment

0.20 (0.04)

0.28 (< 0.01)

0.26 (0.03)

0.24 (< 0.01)

Adverse events (symptomatic ARIA-E): 5% increment

 − 0.26 (0.03)

0.25 (< 0.01)

 − 0.52 (0.04)

0.41 (0.01)

Treatment duration: 1-year increment

 − 0.02 (0.01)

0.13 (< 0.01)

 − 0.13 (0.01)

0.15 (< 0.01)

Treatment titration (at initiation): yes vs. no

 − 0.19 (0.04)

0.57 (< 0.01)

 − 0.07 (0.02)

0.35 (< 0.01)

Treatment administration: IV every 4 vs. 2 weeks

0.20 (0.09)

0.83 (0.01)

1.00 (0.12)

1.16 (0.02)

Treatment administration: SC vs. IV every 2 weeks

0.07 (0.05)

0.72 (0.01)

0.42 (0.10)

1.10 (0.01)

  1. ARIA-E Amyloid-related imaging abnormalities-edema, IV Intravenous, SD Standard deviation, SE Standard error, SC Subcutaneous
  2. aA utility is a preference-based score, with higher scores indicating higher preferences for that attribute. For each attribute, a larger mean partial utility indicates a greater average preference in the sample, and a larger SD partial utility indicates greater heterogeneity in preference within the sample